Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy.

Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy. Cancer J. 2020 Jan/Feb;26(1):13-20 Authors: Glicksman RM, Berlin A Abstract The use of combination RT and androgen deprivation therapy in many prostate cancer curative-intent treatment scenarios is supported by level 1 evidence. However, in our current clinical paradigm, we have no ability to determine a priori which patients truly benefit from combination therapy and therefore apply the combination RT and androgen deprivation therapy intensification strategy to all patients, which results in overtreatment or undertreatment of the majority of our patients. Genomics has the ability to more deeply and objectively characterize the disease, in turn refining our prognostication capabilities and enabling the individualization of treatments. We review the commercially available prostate cancer genomic tests, focusing on those able to predict patient outcomes following radiotherapy or guide radiotherapy treatment decisions. PMID: 31977380 [PubMed - in process]
Source: Cancer Journal - Category: Cancer & Oncology Authors: Tags: Cancer J Source Type: research